Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 4/20 | 0.31 |
| ▸ | PI4KA | P42356 | 2/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11591791 | 0.81 | HTT (0.33) | CYP3A4CYP1A2HIF1AMKNK1EGFR | |
| SCHEMBL2116843 | 0.81 | PDPK1 (0.33) | CYP3A4CYP1A2HIF1AMKNK1EGFR | |
| SCHEMBL22892194 | 0.79 | CSNK2A1 (0.33) | CYP3A4CYP1A2HIF1AMKNK1EGFR | |
| SCHEMBL21913 | 0.79 | YTHDC1 (0.47) | CYP3A4CYP1A2HIF1ACDK2HTT | |
| SCHEMBL18640373 | 0.79 | CYP3A4 (0.42) | CYP3A4CYP1A2HIF1ACDK2HTT | |
| SCHEMBL6272986 | 0.78 | YTHDC1 (0.46) | CYP3A4CYP1A2HIF1ACDK2HTT | |
| SCHEMBL10918759 | 0.78 | YTHDC1 (0.46) | CYP3A4CYP1A2HIF1ACDK2HTT | |
| SCHEMBL22118770 | 0.77 | BRD4 (0.40) | MKNK1EGFRBRD4TOP2ABRAF | |
| SCHEMBL5437606 | 0.77 | MKNK1 (0.38) | MKNK1EGFRXDHBRD4TOP2A | |
| SCHEMBL405822 | 0.76 | PDPK1 (0.34) | CYP3A4CYP1A2HIF1AEGFRCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-9677067-B2 | Compositions and methods for synthetic gene assembly | Twist Bioscience Corporation (US) | 2017-06-13 | — | — | US | claimed |
| US-20170159044-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2017-06-08 | — | — | US | claimed |
| US-20160264958-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2016-09-15 | — | — | US | claimed |
| WO-2016126987-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation (US) | 2016-08-11 | — | — | WO | claimed |
| EP-2694524-B1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | US HEALTH (US) | 2016-05-18 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | TheUnited ofAmerica,asrepresentedbythe Secre -tary,Department ofHealthand Human Service (US) | 2014-02-20 | — | — | US | claimed |
| EP-2694524-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138530-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-10-11 | — | — | WO | claimed |
| US-7807356-B2 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | claimed |
| US-7524942-B2 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. (US) | 2009-04-28 | — | — | US | claimed |
| US-20080124708-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2008-05-29 | — | — | US | claimed |
| US-20070212697-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2007-09-13 | — | — | US | claimed |
| EP-4748940-A2 | DE NOVO SYNTHESISED GENE LIBRARIES | Twist Bioscience Corporation (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124708-A1 | Labeled nucleotide composition | RNGTT, RNMT, NOP2 | CYP3A4 3828/4885CYP1A2 3227/4885HIF1A 4231/4885 |
| US-20070212697-A1 | Labeled nucleotide composition | RNGTT, RNMT, NOP2 | CYP3A4 3828/4885CYP1A2 3227/4885HIF1A 4231/4885 |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | NSUN2, RNGTT, RNMT | CYP3A4 3895/4885CYP1A2 3150/4885HIF1A 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.